Bio-Rad's revenue has plateaued near $650M per quarter with trailing growth of only 0.7%, while gross margin has drifted from 55.6% in Q2 2024 to 50.1% in Q3 2026, suggesting pricing and mix pressure rather than a reaccelerating franchise.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has held near $650M per quarter with only 0.7% trailing growth while gross margin compressed from 55.6% to 50.1% and reported operating margin turned negative at -7.6% in Q3 2026, suggesting weak operating leverage.
Bio-Rad Laboratories is a global leader in life science research and clinical diagnostic markets, with a broad range of innovative products.
There is a bullish thesis on Bio-Rad Laboratories (BIO) highlighted by Stock Analysis Compilation, suggesting positive investor sentiment.
As of Nov 20th, BIO's forward P/E was 28.49, indicating potential value for investors based on earnings growth expectations.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $2.65+18.8% vs $2.23 | $656M+1.0% vs $650M |
Q3 2026 Aug 4, 2026 | $2.62+49.7% vs $1.75 | $651M+4.3% vs $624M |
Q2 2026 Apr 30, 2026 | $1.89-4.1% vs $1.97 | $592M+0.4% vs $590M |
Q1 2026 Feb 12, 2026 | $2.51-2.3% vs $2.57 | $693M+0.6% vs $689M |
Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs
Bio-Rad Laboratories NYSE: BIO reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset weakness in parts of its life sciences business.
Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.26 per share a year ago.
Benchmark BIO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bio-Rad Laboratories, Inc. (BIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $381.57 | $10.27B | 10.05 | 0.65% | 39.45% | 14.07% | — | |
| $694.76 | $258.19B | 36.39 | 3.91% | 14.96% | 13.3% | 0.24% | |
| $230.25 | $161.86B | 37.58 | 2.9% | 16.91% | 8.18% | 0.54% | |
| $61.31 | $9.33B | -75.77 | 2.08% | -3.51% | -5.05% | 0.24% | |
| $173.49 | $9.79B | -831.29 | 16.36% | -1.47% | -0.56% | — | |
| $337.52 | $16.26B | 408.03 | -0.85% | 1.01% | 1.3% | — |
Bio-Rad Laboratories, Inc. (BIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bio-Rad Laboratories, Inc. (BIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Aug 4, 2026·SEC
Apr 30, 2026·SEC
Get notified when BIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bio-Rad Laboratories, Inc. (BIO) stock FAQ — growth, dividends, profitability & financials explained
Bio-Rad Laboratories, Inc. (BIO) reported $2.58B in revenue in fiscal year 2025, which is also its trailing twelve months. That is 517% more than the $418.8M of fiscal year 1996.
Bio-Rad Laboratories, Inc. (BIO) grew revenue by 1.4% over the trailing twelve months, compared with the twelve months before.
Yes. Bio-Rad Laboratories, Inc. (BIO) earned $1.02B in net income over the trailing twelve months (a 39.5% net margin).
Bio-Rad Laboratories, Inc. (BIO) had a return on equity (ROE) of 14.1% over the trailing twelve months. That is in line with the market's typical 10-15%.
Bio-Rad Laboratories, Inc. (BIO) generated $329.1M in free cash flow over the trailing twelve months.
